Patents Assigned to Sankyo Company Limited
  • Patent number: 11884678
    Abstract: The present disclosure provides a method for efficiently producing and providing compounds having a spirooxindole skeleton, for example compounds having a spirooxindole skeleton and having antitumor activity that inhibit the interaction between Mdm2 protein and p53 protein, or intermediates thereof, using an asymmetric catalyst. Compounds having optically active tricyclic dispiroindole skeletons are obtained through catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: January 30, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Motoshi Yamauchi, Keiji Nakayama
  • Publication number: 20240026030
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Application
    Filed: September 12, 2023
    Publication date: January 25, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
  • Patent number: 11866472
    Abstract: To provide a novel pharmaceutical use of a peptide. A pharmaceutical composition for the treatment or prevention of retinitis pigmentosa, comprising a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits the protease activity.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 9, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Tatsuya Inoue
  • Publication number: 20240002425
    Abstract: The present invention provides a novel compound or a pharmaceutically acceptable salt thereof which has a TLR4 activating effect and can be used as an immunostimulant or an adjuvant in vaccines or allergen immunotherapy. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In this context, X, Y, Z and n in the formula (I) are each as defined herein.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 4, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Kobayashi, Tatsuya Oka, Yoshiko Fukuyama
  • Publication number: 20240000954
    Abstract: A complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention. Furthermore, a complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention.
    Type: Application
    Filed: November 11, 2021
    Publication date: January 4, 2024
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken ISHII, Takato KUSAKABE, Yuji KASUYA, Nao JONAI, Fumihiko TAKESHITA, Isshin TANAKA, Emi KUROSAWA, Kyosuke SUZUKI, Tetsufumi KOGA, Yoshihiro MIYAJI
  • Patent number: 11859006
    Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 2, 2024
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Sho Tsukamoto, Keigo Kumagai, Shinnosuke Tsuji
  • Publication number: 20230414778
    Abstract: A pharmaceutical composition and a method of treatment having excellent antitumor effect and safety are provided. A pharmaceutical composition and a method of treatment wherein an antibody-drug conjugate, in which a drug-linker and an antibody are bound by a thioether bond represented by the following formula (A represents the binding position with an antibody), and a SIRP?-CD47 interaction inhibitor, such as an anti-SIRP? antibody, are administrated in combination. Alternatively, a pharmaceutical composition and a method of treatment wherein said antibody-drug conjugate and SIRP?-CD47 interaction inhibitor, such as an anti-SIRP? antibody, are administrated in combination and are used for the treatment of a disease improved by an action of activating antitumor immunity.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 28, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Mayumi SUE, Takuya TSUBAKI, Yoko ISHIMOTO
  • Patent number: 11845786
    Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: December 19, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Masakazu Tamura
  • Publication number: 20230398230
    Abstract: A therapeutic agent for mesothelioma comprising, as an active component, an anti-B7-H3 antibody-drug conjugate in which a drug-linker represented by the following formula, wherein A represents a connecting position to an anti-B7-H3 antibody; is conjugated to the anti-B7-H3 antibody via a thioether bond, and/or a method of treatment for mesothelioma, comprising administering the anti-B7-H3 antibody-drug conjugate to a subject in need of treatment for mesothelioma.
    Type: Application
    Filed: November 11, 2021
    Publication date: December 14, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Michiko YAMATO
  • Patent number: 11834427
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: December 5, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Publication number: 20230372527
    Abstract: A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-HER2 antibody drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (I).
    Type: Application
    Filed: October 8, 2021
    Publication date: November 23, 2023
    Applicants: AstraZeneca UK Limited, Daiichi Sankyo Company, Limited
    Inventors: Jerome Thomas METTETAL, II, Azadeh Cheraghchi Bashi ASTANEH, Elisabetta LEO, Yann WALLEZ
  • Patent number: 11806339
    Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: November 7, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Takeshi Jimbo
  • Publication number: 20230348616
    Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 2, 2023
    Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
  • Publication number: 20230348522
    Abstract: The present invention provides a crystalline 2,4-bridged common intermediate useful for producing a plurality of ENA monomers, a method for stereoselectively producing the intermediate, and a method for efficiently producing ENA monomers using the intermediate.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 2, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Michida, Kazutoshi Ukai, Yuzo Abe, Moe Matsumoto, Makoto Yamaoka, Kei Kurahashi
  • Publication number: 20230340118
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
  • Patent number: 11795236
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: October 24, 2023
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
  • Publication number: 20230330248
    Abstract: [Problem] It is desired to develop an antibody-drug conjugate capable of being systemically administered and delivering a STING agonist specifically to a target cells or organ (for example, a tumor lesion), and a therapeutic agent and/or therapeutic method using the antibody-drug conjugate for diseases related to STING agonist activity, for example, diseases (for example, cancers) to which immunostimulation therapy can be applied. [Solution] The present invention provides a novel antibody-CDN derivative conjugate which can be systemically administered and exhibits an antitumor effect against an antigen-expressing tumor.
    Type: Application
    Filed: March 5, 2021
    Publication date: October 19, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masayuki ISHIZAKI, Osamu SUZUKI, Mariko KYUTOKU, Hiroshi YUKIURA, Kyoko HARA, Masataka CHIHARA, Takafumi OTSUKA, Teiji WADA
  • Publication number: 20230331700
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.
    Type: Application
    Filed: November 21, 2022
    Publication date: October 19, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi
  • Publication number: 20230330243
    Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 19, 2023
    Applicants: Daiichi Sankyo Company, Limited, AstraZeneca UK Limited
    Inventors: Jerome Thomas METTETAL, II, Stephen Thomas DURANT, Azadeh Cheraghchi Bashi ASTANEH, Alan Yin Kai LAU, Yann WALLEZ
  • Publication number: 20230293714
    Abstract: A pharmaceutical composition, wherein an anti-HER2 antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an anti-HER2 antibody) is conjugated to the anti-HER2 antibody via a thioether bond, and a HER dimerization inhibitor are administered in combination, and/or a method of treatment, wherein the anti-HER2 antibody-drug conjugate and a HER dimerization inhibitor are administrated in combination to a subject.
    Type: Application
    Filed: July 19, 2021
    Publication date: September 21, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Yasuki KAMAI